Protalix BioTherapeutics (PLX) Misses Q2 EPS by 6c
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.62 --0%
Revenue Growth %: -49.8%
Financial Fact:
RESEARCH AND DEVELOPMENT EXPENSES, NET: -5.06M
Today's EPS Names:
VAXX, NMRD, EGRX, More
Revenue Growth %: -49.8%
Financial Fact:
RESEARCH AND DEVELOPMENT EXPENSES, NET: -5.06M
Today's EPS Names:
VAXX, NMRD, EGRX, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q2 EPS of ($0.11), $0.06 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $8.75 million versus the consensus estimate of $15.1 million.
Cash, cash equivalents and short-term bank deposits were approximately $28.6 million at June 30, 2022.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
- Cellectar Biosciences (CLRB) Misses Q2 EPS by 9c
- Intuitive Machines, Inc. (LUNR) Misses Q2 EPS by 20c, Misses on Revenue; Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
